4.7 Article

Ten-year results of hypofractionated whole breast radiotherapy and intraoperative electron boost in premenopausal women

Journal

RADIOTHERAPY AND ONCOLOGY
Volume 177, Issue -, Pages 71-80

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2022.10.025

Keywords

Intraoperative electron radiotherapy; Breast cancer; Boost; Outcome

Funding

  1. Italian Association for Cancer Research
  2. Jacqueline Seroussi Memorial Foundation for Cancer Research
  3. Umberto Veronesi Foundation
  4. American Italian Cancer Foundation
  5. Lombardy Region
  6. Italian Ministry of Health
  7. Ricerca Corrente

Ask authors/readers for more resources

The study evaluated the outcome of intraoperative electron boost and hypofractionated whole breast irradiation for breast cancer in young women. The treatment achieved excellent local control but resulted in tumor bed fibrosis.
Aim: To evaluate outcome of intraoperative electron boost (IOERT) and hypofractionated whole breast irradiation (HWBI) for breast cancer (BC) in young women.Methods and Materials: Women aged <= 48 with pT1-2 N0-1 BC received 12 Gy IOERT boost during conservative surgery followed by 3-dimensional conformal HWBI in 13 fractions (2.85 Gy/die). Local relapses (LR) and survival (disease-free, DFS; specific, BCSS; overall, OS) were analyzed.Results: 481 consecutive BC patients, mostly node negative, with median age of 42 were treated between 2004 and 2014. Median tumor size was 1.48 cm and median IOERT collimator was 4 cm. After 25-day mean interval, HWBI was delivered. At a median follow-up of 9.6 years, there were 23 LRs (4.8 %, 9 of which were in the boost region). Ten-year LR cumulative incidence was 4.1 % (95 %CI, 2.5-6.3). Over time, local control rate decreased for Luminal A and HER2 positive with negative hormonal receptors, while remained steady for triple negative. At multivariate analysis, LR predictors included age < 40, extensive intraductal component and the use of 4-cm IOERT collimator size. Ten-year survival outcomes were as follows: DFS 80.0 % (95 % CI, 75.8-83.5), BCSS 97.5 % (95 % CI, 95.5-98.6 %), OS 96.5 % (95 % CI, 94.3- 97.9). Luminal B HER2 negative had the worse survival outcomes. Perioperative complications were uncommon (16.4 %), acute toxicity was mild (<2% Grade 3), but moderate/severe fibrosis was described in 40.8 % of the cases. Cosmesis was scored as excellent/good in 86 % of the cases.Conclusions: ELIOT boost and HWBI achieved an excellent local control at the cost of tumor bed fibrosis. IOERT boost dose lower than 12 Gy is advisable.(c) 2022 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 177 (2022) 71-80

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available